AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug
MT Newswires Live
Sep 18
AstraZeneca (AZN) said Friday the US Food and Drug Administration granted priority review to its Alexion unit's biologics license application for efzimfotase alfa to treat patients aged two years and older with hypophosphatasia, a genetic bone disorder.
The health regulator is expected to make a regulatory decision in H1 2027, and the filing is supported by results from three phase 3 trials in children and adults, the company said.
The proposed biweekly treatment is designed to address skeletal abnormalities and functional issues associated with the disorder, AstraZeneca said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.